Characterization of chikungunya virus-like particles

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Noranate, Nitchakarn ^a   Takeda, Naokazu ^a,c   Chetanachan, Prukswan ^b   Sittisaman, Pathompong ^b   A Nuegoonpipat, Atchareeya ^b   Anantapreecha, Surapee ^b  

^a Thailand Japan Research Collaboration Center on Emerging and Re emerging Infections RCC ERI   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; VIRUS ANTIBODY; VIRUS PROTEIN; PRIMER DNA; VIRUS ANTIGEN;

ANTIGENICITY; ARTICLE; CELL LYSATE; CHIKUNGUNYA; CONTROLLED STUDY; DENSITY; EXPRESSION VECTOR; GENE INSERTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; NONHUMAN; PROTEIN EXPRESSION; SUPERNATANT; TRANSMISSION ELECTRON MICROSCOPY; VIRION; VIRUS LIKE AGENT; VIRUS MORPHOLOGY; CHIKUNGUNYA VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEK293 CELL LINE; IMMUNOELECTRON MICROSCOPY; IMMUNOLOGY; NUCLEOTIDE SEQUENCE; ULTRASTRUCTURE;

CHIKUNGUNYA VIRUS;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BASE SEQUENCE; CHIKUNGUNYA VIRUS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, IMMUNOELECTRON; VIRION;

EID: 84907541132     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108169     Document Type: Article

References (46)

1. Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT (2012) Chikungunya: A re-emerging virus. Lancet 379: 662-671.
2. Sawabe K, Isawa H, Hoshino K, Sasaki T, Roychoudhury S, et al. (2010) Hostfeeding habits of Culex pipiens and Aedes albopictus (Diptera: Culicidae) collected at the urban and suburban residential areas of Japan. J Med Entomol 47: 442-450.
3. Rochlin I, Ninivaggi DV, Hutchinson ML, Farajollahi A (2013) Climate change and range expansion of the Asian tiger mosquito (Aedes albopictus) in Northeastern USA: Implications for public health practitioners. PLoS One 8: e60874.
4. Fischer D, Thomas SM, Suk JE, Sudre B, Hess A, et al. (2013) Climate change effects on Chikungunya transmission in Europe: geospatial analysis of vector's climatic suitability and virus' temperature requirements. Int J Health Geogr 12:51
5. Tsetsarkin KA, Weaver SC (2011) Sequential adaptive mutations enhance efficient vector switching by Chikungunya virus and its epidemic emergence. PLoS Pathog 7: e1002412.
6. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S (2007) A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 3: e201.
7. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, et al. (2007) Infection with chikungunya virus in Italy: An outbreak in a temperate region. Lancet 370: 1840-1846.
8. Hapuarachchi HC, Bandara KB, Sumanadasa SD, Hapugoda MD, Lai YL, et al. (2010) Re-emergence of Chikungunya virus in South-east Asia: virological evidence from Sri Lanka and Singapore. J Gen Virol 91: 1067-1076.
9. Kariuki Njenga M, Nderitu L, Ledermann JP, Ndirangu A, Logue CH, et al. (2008) Tracking epidemic Chikungunya virus into the Indian Ocean from East Africa. J Gen Virol 89: 2754-2760.
10. Ross RW (1956) The Newala epidemic. III. The virus: Isolation, pathogenic properties and relationship to the epidemic. J Hyg (Lond) 54: 177-191.
11. Strauss JH, Strauss EG (1994) The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 58: 491-562.
12. Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM (2010) Virus-like particles in vaccine development. Expert Rev Vaccines 9: 1149-1176.
13. Brady JN, Consigli RA (1978) Chromatographic separation of the polyoma virus proteins and renaturation of the isolated VP1 major capsid protein. J Virol 27: 436-442.
14. Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM (2011) Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev Vaccines 10: 1569-1583.
15. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, et al. (2010) A viruslike particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 16: 334-338.
16. Akahata W and Nabel GJ (2012) A specific domain of the chikungunya virus e2 protein regulates particle formation in human cells: Implications for alphavirus vaccine design. J Virol 86: 8879-8883.
17. Zhi N, Wan Z, Liu X, Wong S, Kim DJ, et al. (2010) Codon optimization of human parvovirus B19 capsid genes greatly increases their expression in nonpermissive cells. J Virol 84: 13059-13062.
18. Kishishita N, Takeda N, Anuegoonpipat A, Anantapreecha S (2013) Development of a pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection. J Clin Microbiol 51: 1389-1395.
19. Eckels KH, Harrison VR, Hetrick FM (1970) Chikungunya virus vaccine prepared by Tween-ether extraction. Appl Microbiol 19: 321-325.
20. Thiboutot MM, Kannan S, Kawalekar OU, Shedlock DJ, Khan AS, et al. (2010) Chikungunya: A potentially emerging epidemic? PLoS Negl Trop Dis 4: e623.
21. McClain DJ, Pittman PR, Ramsburg HH, Nelson GO, Rossi CA, et al. (1998) Immunologic interference from sequential administration of live attenuated alphavirus vaccines. J Infect Dis 177: 634-641.
22. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, et al. (2000) Phase II safety and immunogenicity study of live chikungunya virus vaccine TSIGSD- 218. Am J Trop Med Hyg 62: 681-685.
23. Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, et al. (2009) Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 27: 2513-2522.
24. Brandler S, Ruffie C, Combredet C, Brault JB, Najburg V, et al. (2013) A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 31: 3718-3725.
25. Wang E, Kim DY, Weaver SC, Frolov I (2011) Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response. J Virol 85: 9249-9252.
26. Muthumani K, Lankaraman KM, Laddy DJ, Sundaram SG, Chung CW, et al. (2008) Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 26: 5128-5134.
27. Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, et al. (2011) A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 5: e928.
28. Metz SW, Gardner J, Geertsema C, Le TT, Goh L, et al. (2013) Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl Trop Dis 7: e2124.
29. Kumar M, Sudeep AB, Arankalle VA (2012) Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 30: 6142-6149.
30. Ivanova L, Schlesinger MJ (1993) Site-directed mutations in the Sindbis virus E2 glycoprotein identify palmitoylation sites and affect virus budding. J Virol 67: 2546-2551.
31. Strauss EG, Lenches EM, Strauss JH (2002) Molecular genetic evidence that the hydrophobic anchors of glycoproteins E2 and E1 interact during assembly of alphaviruses. J Virol 76: 10188-10194.
32. Sjoberg M, Garoff H (2003) Interactions between the transmembrane segments of the alphavirus E1 and E2 proteins play a role in virus budding and fusion. J Virol 77: 3441-3450.
33. Lopez S, Yao JS, Kuhn RJ, Strauss EG, Strauss JH (1994) Nucleocapsidglycoprotein interactions required for assembly of alphaviruses. J Virol 68: 1316-1323.
34. Jose J, Przybyla L, Edwards TJ, Perera R, Burgner JW 2nd, et al. (2011) Interactions of the cytoplasmic domain of Sindbis virus E2 with nucleocapsid cores promote alphavirus budding. J Virol 86: 2585-2599.
35. Lu YE, Cassese T, Kielian M (1999) The cholesterol requirement for sindbis virus entry and exit and characterization of a spike protein region involved in cholesterol dependence. J Virol 73: 4272-4278.
36. Umashankar M, Sanchez-San Martin C, Liao M, Reilly B, Guo A, et al. (2008) Differential cholesterol binding by class II fusion proteins determines membrane fusion properties. J Virol 82: 9245-9253.
37. Vashishtha M, Phalen T, Marquardt MT, Ryu JS, Ng AC, et al. (1998) A single point mutation controls the cholesterol dependence of Semliki Forest virus entry and exit. J Cell Biol 140: 91-99.
38. Lescar J, Roussel A, Wien MW, Navaza J, Fuller SD, et al. (2001) The Fusion glycoprotein shell of Semliki Forest virus: An icosahedral assembly primed for fusogenic activation at endosomal pH. Cell 105: 137-148.
39. Wahlberg JM, Garoff H (1992) Membrane fusion process of Semliki Forest virus. I: Low pH-induced rearrangement in spike protein quaternary structure precedes virus penetration into cells. J Cell Biol 116: 339-348.
40. Sanchez-San Martin C, Liu CY, Kielian M (2009) Dealing with low pH: entry and exit of alphaviruses and flaviviruses. Trends Microbiol 17: 514-521.
41. Warter L, Lee CY, Thiagarajan R, Grandadam M, Lebecque S, et al. (2011) Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J Immunol 186: 3258-3264.
42. Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, et al. (2009) Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis 200: 516-523.
43. Lum FM, Teo TH, Lee WW, Kam YW, Renia L, et al. (2013) An essential role of antibodies in the control of Chikungunya virus infection. J Immunol 190: 6295-6302.
44. Metz SW, van den Doel P, Geertsema C, Osterhaus AD, Vlak JM, et al. (2013) Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine.
45. Deml L, Speth C, Dierich MP, Wolf H, Wagner R (2005) Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 42: 259-277.
46. Gardner J, Anraku I, Le TT, Larcher T, Major L, et al. (2010) Chikungunya virus arthritis in adult wild-type mice. J Virol 84: 8021-8032.